359 related articles for article (PubMed ID: 25740198)
21. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
22. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
Corona JC; Gimenez-Cassina A; Lim F; Díaz-Nido J
J Neurosci Res; 2010 Jul; 88(9):1943-50. PubMed ID: 20143419
[TBL] [Abstract][Full Text] [Related]
23. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
[TBL] [Abstract][Full Text] [Related]
24. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
[TBL] [Abstract][Full Text] [Related]
25. Formation of electrophilic oxidation products from mitochondrial cardiolipin in vitro and in vivo in the context of apoptosis and atherosclerosis.
Zhong H; Lu J; Xia L; Zhu M; Yin H
Redox Biol; 2014; 2():878-83. PubMed ID: 25061570
[TBL] [Abstract][Full Text] [Related]
26. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
[TBL] [Abstract][Full Text] [Related]
27. Non-Reproducibility of Oral Rotenone as a Model for Parkinson's Disease in Mice.
Niederberger E; Wilken-Schmitz A; Manderscheid C; Schreiber Y; Gurke R; Tegeder I
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293513
[TBL] [Abstract][Full Text] [Related]
28. Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.
Tapias V; Cannon JR; Greenamyre JT
Neurobiol Aging; 2014 May; 35(5):1162-76. PubMed ID: 24315037
[TBL] [Abstract][Full Text] [Related]
29. Characterization of cardiolipins and their oxidation products by LC-MS analysis.
Tyurina YY; Domingues RM; Tyurin VA; Maciel E; Domingues P; Amoscato AA; Bayir H; Kagan VE
Chem Phys Lipids; 2014 Apr; 179():3-10. PubMed ID: 24333544
[TBL] [Abstract][Full Text] [Related]
30. Phenothiazine normalizes the NADH/NAD
Tapias V; McCoy JL; Greenamyre JT
Redox Biol; 2019 Jun; 24():101164. PubMed ID: 30925294
[TBL] [Abstract][Full Text] [Related]
31. Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson's disease.
Farombi EO; Awogbindin IO; Olorunkalu PD; Ogbuewu E; Oyetunde BF; Agedah AE; Adeniyi PA
Psychopharmacology (Berl); 2020 Nov; 237(11):3225-3236. PubMed ID: 32651640
[TBL] [Abstract][Full Text] [Related]
32. Aging-related rotenone-induced neurochemical and behavioral deficits: role of SIRT2 and redox imbalance, and neuroprotection by AK-7.
Wang X; Guan Q; Wang M; Yang L; Bai J; Yan Z; Zhang Y; Liu Z
Drug Des Devel Ther; 2015; 9():2553-63. PubMed ID: 26089639
[TBL] [Abstract][Full Text] [Related]
33. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
[TBL] [Abstract][Full Text] [Related]
34. The Mechanism of SNHG8/Microrna-421-3p/Sorting Nexin 8 Axis on Dopaminergic Neurons in Substantia Nigra in a Mouse Model of Parkinson's Disease.
Zhou S; Zhou X; Jiang Z; Ma J; Li Y; Qian Z; Li H
Neurochem Res; 2023 Mar; 48(3):942-955. PubMed ID: 36401052
[TBL] [Abstract][Full Text] [Related]
35. Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons.
Wu YN; Johnson SW
Neuroscience; 2011 Nov; 195():138-44. PubMed ID: 21884756
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota-induced CXCL1 elevation triggers early neuroinflammation in the substantia nigra of Parkinsonian mice.
Ma XZ; Chen LL; Qu L; Li H; Wang J; Song N; Xie JX
Acta Pharmacol Sin; 2024 Jan; 45(1):52-65. PubMed ID: 37674043
[TBL] [Abstract][Full Text] [Related]
37. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
38. A highly reproducible rotenone model of Parkinson's disease.
Cannon JR; Tapias V; Na HM; Honick AS; Drolet RE; Greenamyre JT
Neurobiol Dis; 2009 May; 34(2):279-90. PubMed ID: 19385059
[TBL] [Abstract][Full Text] [Related]
39. Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model.
Sun C; Wang Y; Mo M; Song C; Wang X; Chen S; Liu Y
Biomed Res Int; 2019; 2019():6843265. PubMed ID: 30949504
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
